2017 Annual Meeting | C30 - Cerebrovascular Disease I: Prevention

Date Sunday 04/23/17

Time 07:00 AM - 09:00 AM Add To Calendar

Session Format This program will be presented both in-person and online

On Demand This program is not expected to be available in the meeting's On Demand product.

Event Type Seminar

Director(s) Larry B. Goldstein, MD, FAHA, FAAN

Topic(s)

Learning Objectives Participants should be able to recommend appropriate lifestyle changes for stroke prevention, select patients for treatment with a statin, discuss risks and benefits of carotid revascularization for stroke prevention, and identify patients with atrial fibrillation who would benefit from treatment with warfarin or a novel oral anticoagulant and choose appropriate reversal strategies.

CME Available 2.00 CME credits

Core Competencies Patient Care & Procedural Skills, Interpersonal and Communication Skills, Practice-based Learning and Improvement

Recommended Audience Trainee, General Neurologist, Specialist Neurologist, Non-neurologist, Advanced Practice Provider

Teaching Styles Didactic, Interactive

Event Timeline
07:00 AM - 07:20 AM	Luncheon	Introduction and the Importance of Lifestyle Larry B. Goldstein, MD, FAHA, FAAN
07:20 AM - 07:25 AM	Q&A	Questions and Answers Larry B. Goldstein, MD, FAHA, FAAN
07:25 AM - 07:45 AM	Speaker	Statins for Primary and Secondary Stroke Prevention Larry B. Goldstein, MD, FAHA, FAAN
07:45 AM - 07:50 AM	Q&A	Questions and Answers Larry B. Goldstein, MD, FAHA, FAAN
07:50 AM - 08:10 AM	Speaker	Carotid Revascularization for Stroke Prevention Seemant Chaturvedi, MD, FAHA, FAAN
08:10 AM - 08:15 AM	Q&A	Questions and Answers Seemant Chaturvedi, MD, FAHA, FAAN
08:15 AM - 08:35 AM	Speaker	Anticoagulants for Stroke Prevention in Patients with Atrial Fibrillation Karen L. Furie, MD
08:35 AM - 08:40 AM	Q&A	Questions and Answers Karen L. Furie, MD
08:40 AM - 09:00 AM	Discussion	General Discussion

Faculty Disclosures
Larry B. Goldstein, MD, FAHA, FAAN	The institution of Dr. Goldstein has received research support from NIH. The institution of Dr. Goldstein has received research support from NIH. The institution of Dr. Goldstein has received research support from NIH. The institution of Dr. Goldstein has received research support from NIH. The institution of Dr. Goldstein has received research support from NIH. The institution of Dr. Goldstein has received research support from Janssen. Dr. Goldstein has received publishing royalties from a publication relating to health care.
Seemant Chaturvedi, MD, FAHA, FAAN	Dr. Chaturvedi has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Astra Zeneca. Dr. Chaturvedi has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for University of Calgary. Dr. Chaturvedi has received personal compensation in the range of $10,000-$49,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for American Heart Association. Dr. Chaturvedi has received personal compensation in the range of $10,000-$49,999 for serving as an Expert Witness for Ramar & Paradiso. Dr. Chaturvedi has received personal compensation in the range of $10,000-$49,999 for serving as an Expert Witness for Cole, Scott, Kissane. The institution of Dr. Chaturvedi has received research support from NINDS.
Karen L. Furie, MD	The institution of Dr. Furie has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Janssen/BMS. Dr. Furie has received personal compensation in the range of $50,000-$99,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for BMJ/JNNP. The institution of Dr. Furie has received research support from NINDS.

��ɫ��

��ɫ��